Clinical SNP detection by the SmartAmp method

Methods in Molecular Biology

Volumn 1015, Issue , 2013, Pages 55-69

  Ishikawa, Toshihisa ^a   Hayashizaki, Yoshihide ^a  

^a RIKEN   (Japan)

Author keywords

ABCB1 (MDR1); ABCC11; Adverse reaction; CYP2C9; Irinotecan; Personalized medicine; Point of care; UGT1A1; VKORC1; Warfarin

Indexed keywords

DNA POLYMERASE; GENOMIC DNA; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; SINGLE STRANDED DNA;

ALICYCLOBACILLUS ACIDOCALDARIUS; ALLELE; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; MEDICAL DEVICE; NONHUMAN; PH; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84880363478     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-435-7_3     Document Type: Article

References (27)

1. Mitani Y et al (2007) Rapid SNP diagnostics using asymmetric isothermal amplifi cation and a new mismatch-suppression technology. Nat Methods 4:257-262
2. Mitani Y et al (2009) A rapid and cost-effective SNP detection method: Application of SmartAmp2 to pharmacogenomics research. Pharmacogenomics 10:1187-1197
3. Watanabe J et al (2007) Use of a competitive probe in assay design for genotyping of the UGT1A1*28 microsatellite polymorphism by the smart amplifi cation process. Biotechniques 43:479-484
4. Toyoda Y et al (2009) Earwax, osmidrosis, and breast cancer: Why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type? FASEB J 23: 2001-2013
5. Yoshiura K et al (2006) A SNP in the ABCC11 gene is the determinant of human earwax type. Nat Genet 38:324-330
6. Miura K et al (2007) A strong association between human earwax-type and apocrine colostrum secretion from the mammary gland. Hum Genet 121:631-633
7. Ota I et al (2010) Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11. Anticancer Res 30:5189-5194
8. Toyoda Y, Ishikawa T (2010) Pharmacogenomics of human ABC transporter ABCC11 (MRP8): Potential risk of breast cancer and chemotherapy failure. Anticancer Agents Med Chem 10:617-623
9. Kimura Y et al (2011) Optimization of turnback primers in isothermal amplifi cation. Nucleic Acids Res 39:e59
10. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
11. Cannegieter SC et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11-17
12. Fihn SD et al (1993) Risk factors for complications of chronic anticoagulation. Ann Intern Med 118:511-520
13. Aomori T et al (2009) Rapid SNP detection of the cytochrome P-450 (CYP) 2C9 and the vitamin K oxide reductase (VKORC1) gene for the warfarin dose adjustment by Smart- Amplifi cation process version 2. Clin Chem 55:804-812
14. Ando Y et al (2000) Polymorphisms of UDPglucuronosyltransferase gene and irinotecan adverse reactions: A pharmacogenetic analysis. Cancer Res 60:6921-6929
15. Ando Y, Hasegawa Y (2005) Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev 37:565-574
16. Rouits E et al (2004) Relevance of different UGT1A1 polymorphisms in irinotecaninduced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159
17. Iyer L et al (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and adverse reactions. Pharmacogenomics J 2:43-47
18. Innocenti F et al (2004) Genetic variants in the UDP- glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388
19. Marcuello E et al (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682
20. Kitagawa C et al (2005) Genetic polymorphism in the phenobarbital- responsive enhancer module of the UDPglucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 15:35-41
21. Hasegawa Y et al (2006) Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Ann N Y Acad Sci 1086:223-232
22. Innocenti F et al (2002) Haplotype structure of the UDP- glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733
23. Watanabe J et al (2007) Complete suppression of background amplifi cation using competitive probe in a SMart-Amplifi cation process assay for microsatellite polymorphism genotyping of UGT1A1*28. Biotechniques 43:479-484
24. Leschzinger GD et al (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics J 7:154-179
25. Sakurai A et al (2007) Quantitative SAR analysis and molecular dynamic simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1. Biochemistry 46:7678-7693
26. Hüebner C et al (2007) Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev 16: 1185-1192
27. Ishikawa T et al (2010) Emerging new technologies in pharmacogenomics: Rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC transporter ABCB1 (P-gp/MDR1). Pharmacol Ther 126:69-81